Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.
Yuan S, Wang L, Zhang H, Xu F, Zhou X, Yu L, Sun J, Chen J, Ying H, Xu X, Yu Y, Spiliopoulou A, Shen X, Wilson J, Gill D, Theodoratou E, Larsson SC, Li X.
Yuan S, et al. Among authors: xu f, xu x.
EBioMedicine. 2023 Mar;89:104488. doi: 10.1016/j.ebiom.2023.104488. Epub 2023 Feb 24.
EBioMedicine. 2023.
PMID: 36842216
Free PMC article.